Future studies should evaluate the potential of using this therapy for the treatment of hereditary breast cancer due to other genes, including BRCA2. Given that there do not appear to be founder mutations in BRCA2 in Poland, it will be necessary that these studies be conducted in other countries (or provinces) where BRCA2 founder mutations are prevalent (for example, Quebec) [24]. Here, BRCA2 is linked to breast cancer.